Werngard Czechtizky

Werngard Czechtizky is Head of the Medicinal Chemistry Department for Respiratory, Inflammation and Autoimmunity (RIA) at AstraZeneca in Gothenburg, Sweden. She has a track record of delivery of clinical candidates and lead compounds across several therapeutic areas (CV, Diabetes, Pain, CNS, Inflammation and Respiratory), and has continuously implemented state of the art technologies into Medicinal Chemistry. This includes e.g. efficient integration of augmented design methods into projects, setup of New Modalities Chemistry & Analytics capabilities, implementation of automated synthesis, purification and analytics facilities and efficient physchem & eADME profiling workflows. Werngard is part of AZ’s Global Chemistry Council, serves on scientific advisory boards of journals and scientific conferences, and is co-/author of ca 80 publications and patents. She has studied at the Technical University of Graz, Austria, received a PhD from ETH Zürich and a postdoctoral training at Harvard University. Before joining AZ in 2017, she has been working at Aventis, then Sanofi at Frankfurt, Germany.